ArticleMedical oncology (Northwood, London, England)2026
Glycyrrhizin upregulates PTEN and suppresses oncogenic signaling in breast cancer.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer progression is driven by aberrant signaling pathways that include proliferation, apoptosis, and cytoskeletal remodeling. While tamoxifen remains central to breast cancer therapy, its clinical utility is restricted by developing resistance and toxicity, prompting the need for safer alternatives. To this end, glycyrrhizin, a triterpenoid saponin derived from Glycyrrhiza glabra, has shown activity against different cancers, yet its exact role in breast carcinogenesis remains elusive. In the present study, the effects of glycyrrhizin and tamoxifen were evaluated in a 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary carcinoma model. Both treatments significantly delayed tumor onset, reduced incidence, and decreased overall tumor burden. Histopathology revealed that DMBA exposure produced predominantly high-grade adenocarcinomas, whereas preventive glycyrrhizin and tamoxifen markedly reduced tumor grade to well-differentiated lesions. Curative protocols using glycyrrhizin and tamoxifen eliminated high-grade features. Gene expression studies indicated downregulation of oncogenic drivers (c-Myc, stathmin, cyclin D1, RAN, α-tubulin) and suppression of the anti-apoptotic protein Bcl-2. Both agents increased p53 mRNA expression, modulated interferon-γ expression, and decreased HSP84 expression. Importantly, glycyrrhizin uniquely enhanced PTEN mRNA expression versus tamoxifen, suggesting a potential influence on PI3K/AKT-related signaling. Protein expression analysis of cyclin D1 and α-tubulin demonstrated reduced levels, consistent with disrupted cell-cycle progression along with compromised cytoskeletal integrity. Collectively, these findings indicate that glycyrrhizin exerts anticancer activity associated with modulation of multiple cancer-related genes and histopathological regression, with a distinctive impact on PTEN mRNA expression and cytoskeletal regulators. These data support glycyrrhizin as a promising natural compound for breast cancer and warrant further protein-level mechanistic and translational evaluation.
Indexed as
Identifiers
41557209What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.